Thyroid Cancer Trial, Recruiting NCT01247597 Sponsor: National Cancer Institute (NCI) Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT01247597
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of tumor confirmed by a tissue sample (biopsy) called PPB (pleuropulmonary blastoma) and/or another tumor linked to a gene called DICER1
  • You have a known or suspected change (variant) in the DICER1 gene
  • You have been diagnosed with one or more of a specific list of rare tumors that may be linked to the DICER1 gene — including PPB, cystic nephroma, certain ovarian tumors, eye tumors (ocular medulloepithelioma), nasal tumors, Wilms tumor, certain muscle tumors, brain tumors, pituitary tumors, or thyroid cancer — regardless of your family history
  • You are a family member (such as a parent, sibling, child, or other relative) of someone who has one of these conditions, even if you yourself are not affected
  • People of any age are welcome, including newborns of affected individuals
  • Previous treatments of any kind are allowed
  • You or your parent/legal guardian are able and willing to give consent to take part

Who may not be able to join:

  • People whose reported diagnosis cannot be confirmed or verified by medical records or tissue samples

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Douglas R Stewart, M.D., National Cancer Institute (NCI)

Phone: (800) 518-8474

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 February 2011

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Psychosocial and Behavioral Issues; Management Guidelines & Risk-reduction Strategies; Genetic & Environmental Interactions; DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome; Clinical Phenotype; Biospecimen Repository

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov